CoChat

The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine

De Berardis, Domenico, Di Iorio, Giuseppe, Acciavatti, Tiziano, Conti, Chiara, Serroni, Nicola, Olivieri, Luigi, Cavuto, Marilde, Martinotti, Giovanni, Janiri, Luigi, Saverio Moschetta, Francesco, Conti, Pio, Di Giannantonio, Massimo · 2011 · CNS & Neurological Disorders - Drug Targets
Cited by 76

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Major Depressive Disorder (MDD) is an extremely disabling, chronic and recurrent disease. Moreover, subthreshold depressive symptoms often persist during periods of apparent remission. Such symptoms include sleep disturbances, sexual dysfunction, weight gain, fatigue, disinterest, anxiety, and/or emotional blunting, which do not often respond to available antidepressant treatments. Agomelatine is a melatonergic agonist (at both MT1 and MT2 receptors) and serotonin 2C (5-HT2C) receptor antagonist. Agomelatine should be particularly useful in the treatment of MDD because of its unique pharmacological profile, accounting for its effective antidepressant action with a relative lack of serious adverse effects. Several clinical trials confirmed the antidepressant efficacy of agomelatine in patients with MDD, with significant efficacy even in severe manifestations of disease and on residual subtreshold symptoms. This compound showed a relative early onset of action as well as an excellent safety and tolerability profile linked to a low discontinuation rate in MDD patients. Moreover, some data suggest that agomelatine has not only antidepressant effects but also anxiolytic effects, with a potential benefit both on anxiety symptoms associated with MDD and in the treatment of generalised anxiety disorder. This review will summarise the role of the melatonergic system in MDD and will describe the characteristics of agomelatine, focusing on its efficacy and safety in the treatment of MDD. Keywords: Agomelatine, circadian rhythms, efficacy, melatonin, major depressive disorder, tolerability, treatment, NCS-R, STAR D, Circadian Timing System, SCN, N-acetyl-5-methoxytryptamine, Zeitgeber, SPZ, norepinephrine, MDD, DMV, adrenocorticotropin, fluoxetine, duloxetine, hypericum perforatum, low melatonin syndrome, 5-HT2C, 5-HT1A, selective serotonin, SSRI, slow wave sleep, NREM, HAM-D, CYP1A, CYP2C9, CYP2C19, lorazepam, fluconazole, paroxetine, mirtazapine, sleep-phase syndrome, imipramine, Montgomery-Åsberg Depression Rating Scale, CGI, REM, electroconvulsive therapy

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/187152711794488674

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 76

Metadata

Authors
De Berardis, D., Di Iorio, G., Acciavatti, T., Conti, C., Serroni, N., Olivieri, L., Cavuto, M., Martinotti, G., Janiri, L., Saverio Moschetta, F., Conti, P., & Di Giannantonio, M.
Venue
CNS & Neurological Disorders - Drug Targets
Published
2011-02-01
Volume
10
Issue
1
Pages
119-132
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
OpenAlex
W2158816287
Cited by
76
References
16
FWCI
8.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.